Group 1 - The core point of the article is that Qianjin Pharmaceutical has received approval for the registration certificate of hydrochloride rufinamide tablets from the National Medical Products Administration [1] - Qianjin Pharmaceutical's revenue composition for the first half of 2025 is as follows: 55.83% from drug production, 41.72% from drug wholesale and retail, 6.91% from other industries, 1.64% from traditional Chinese medicine materials and decoction pieces, and -6.1% from internal offsets [1] - As of the report date, Qianjin Pharmaceutical has a market capitalization of 5 billion yuan [1]

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

关于变更持续督导独立财务顾问主办人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 国投证券股份有限公司（以下简称"国投证券"）为株洲千金药业股份有限 公司（以下简称"公司"）发行股份及支付现金购买资产暨关联交易（以下简称 "本次重组"）的独立财务顾问，国投证券原指定颜永彬先生、杨晓波先生作为 独立财务顾问主办人。 本次变更后，公司本次重组的持续督导独立财务顾问主办人为颜永彬先生和 黄艺庭先生，持续督导期至中国证券监督管理委员会和上海证券交易所规定的持 续督导义务结束为止。 特此公告。 证券代码：600479 证券简称：千金药业 公告编号：2025-062 株洲千金药业股份有限公司 公司于近日收到国投证券出具的《关于变更株洲千金药业股份有限公司 2024 年度发行股份及支付现金购买资产暨关联交易项目独立财务顾问主办人的 通知》，其原指派的独立财务顾问主办人杨晓波先生因个人工作变动原因不再担 任公司本次重组持续督导独立财务顾问主办人，并指定黄艺庭先生（简历附后） 接替本次重组后续持续督导等相关工作，继续履行相关职责。 20 ...

药品批准文号：国药准字 H20256229 证券代码：600479 证券简称：千金药业 公告编号：2025-061 株洲千金药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，株洲千金药业股份有限公司（以下简称"公司"）下属子公司湖南千 金湘江药业股份有限公司（以下简称"千金湘江药业"）收到国家药品监督管理 局核准签发的盐酸鲁拉西酮片的《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 药品名称：盐酸鲁拉西酮片 剂型：片剂 规格：40mg(按 C28H36N4O2S·HCl 计) 注册分类：化学药品 4 类 药品上市许可持有人：湖南千金湘江药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 二、药品其他相关信息 盐酸鲁拉西酮片用于治疗精神分裂症，最早由 Sunovion Ph ...

Core Viewpoint - Qianjin Pharmaceutical (600479) announced that its subsidiary, Qianjin Xiangjiang Pharmaceutical, received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating schizophrenia [1] Group 1 - The approval of Lurasidone Hydrochloride Tablets marks a key milestone for the company in expanding its therapeutic offerings [1] - This product is specifically indicated for the treatment of schizophrenia, which addresses a critical area in mental health [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the psychiatric medication market [1] Group 1: Company Developments - The approval of Lurasidone Hydrochloride Tablets is aimed at treating schizophrenia, which broadens the therapeutic options available to patients [1] - The drug was originally developed by Sunovion Pharmaceuticals Inc. and was first launched in the United States in October 2010, with domestic import approval granted in January 2019 [1] - Other companies that have received registration for this drug in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] Group 2: Market Insights - According to Morin Data, the domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately 52 million yuan in the first half of 2025, indicating a growing market potential for this medication [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Development - The Lurasidone Hydrochloride Tablets are indicated for the treatment of schizophrenia, originally developed by Sunovion Pharmaceuticals Inc. and launched in the U.S. in October 2010 [1] - The drug was approved for importation into China in January 2019, highlighting its potential in the domestic market [1] Group 2: Market Context - Other companies that have obtained the drug registration certificate in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - According to data from MoSheng Pharmaceuticals, the estimated domestic market sales for Lurasidone Hydrochloride Tablets are approximately 52 million yuan in the first half of 2025, indicating a growing market opportunity [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, marking a significant milestone for the company in the psychiatric medication market [1] Group 1: Drug Approval and Market Context - The drug Lurasidone Hydrochloride Tablets is indicated for the treatment of schizophrenia and was originally developed by Sunovion Pharmaceuticals Inc., first launched in the U.S. in October 2010 and approved for import in China in January 2019 [1] - Other companies that have obtained registration for Lurasidone Hydrochloride Tablets in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - According to data from MoSheng Pharmaceuticals, the domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately 52 million yuan in the first half of 2025 [1] Group 2: R&D Investment - As of the date of the announcement, Qianjin Xiangjiang Pharmaceutical has invested a total of 6.3294 million yuan in the research and development of Lurasidone Hydrochloride Tablets [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received the drug registration certificate for Lurasidone Hydrochloride Tablets from the National Medical Products Administration, marking a significant milestone for the company in the psychiatric medication market [1] Company Summary - Qianjin Xiangjiang Pharmaceutical, a subsidiary of Qianjin Pharmaceutical, has been approved for Lurasidone Hydrochloride Tablets, which are used to treat schizophrenia [1] - The cumulative R&D investment by Qianjin Xiangjiang Pharmaceutical in Lurasidone Hydrochloride Tablets amounts to RMB 6.3294 million [1] Industry Summary - Lurasidone Hydrochloride Tablets were first developed by Sunovion Pharmaceuticals Inc. and launched in the U.S. in October 2010, with domestic approval for import in January 2019 [1] - Other companies that have obtained registration for Lurasidone Hydrochloride Tablets in China include Jiangsu Hengrui Medicine Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. [1] - The domestic market sales for Lurasidone Hydrochloride Tablets are projected to be approximately RMB 52 million in the first half of 2025 [1]

证券代码：600479 证券简称：千金药业 公告编号：2025-062 株洲千金药业股份有限公司 关于变更持续督导独立财务顾问主办人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次变更后，公司本次重组的持续督导独立财务顾问主办人为颜永彬先生和 黄艺庭先生，持续督导期至中国证券监督管理委员会和上海证券交易所规定的持 续督导义务结束为止。 特此公告。 株洲千金药业股份有限公司 2025 年 12 月 13 日 附件：黄艺庭先生简历 黄艺庭先生，保荐代表人、注册会计师，现任国投证券投资银行业务委员会 高级副总裁，曾主持或参与谷数科技 IPO、华来科技 IPO，华纳药厂向不特定对 象发行可转换债券、宁波方正及迦南科技向特定对象发行股票、广州开发区金控 集团非公开发行公司债、东华能源小公募债券等项目，具有丰富的投资银行业务 经验。 国投证券股份有限公司（以下简称"国投证券"）为株洲千金药业股份有限 公司（以下简称"公司"）发行股份及支付现金购买资产暨关联交易（以下简称 "本次重组"）的独立财务顾问，国投证券原指定颜永彬先生、 ...